Lexaria Bioscience Corp expected to post a loss of 11 cents a share - Earnings Preview

Lexaria Bioscience

15/11/2024 21:05

* Lexaria Bioscience Corp  LEXX.OQ   LEXX.O  is expected
to show a
rise in quarterly revenue when it reports  results on November
19 (estimated) for the period ending August 31 2024
    * The Kelowna British Columbia-based  company is expected to
report revenue of $150 thousand, according to the mean estimate
from 2 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Lexaria Bioscience Corp
is for
a loss of 11 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Lexaria
Bioscience Corp is 10.00​, above​ its last closing price
of $2.12. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 May. 31 2024  -0.08       -0.10      -0.13     Missed  -25.8
 Feb. 29 2024  -0.10       -0.10      -0.06     Beat    40
 Jan. 1 0001   -0.11       -0.11      -0.13     Missed  -18.2​
 Aug. 31 2023  -0.17       -0.13      -0.12     Beat    11.1
 ​​May.        -0.25       -0.25      -0.37     Missed  -48
 31 2023                                                
                                                        ​
 Aug. 31 2022              -0.21      -0.24     Missed  -14.3
 This summary was machine generated November 15 at 21:05 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)